**Statement of Changes in Beneficial Ownership**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

---

1. Name and Address of Reporting Person
   **Fink Eric**
   
   (Last)   (First)   (Middle)  
   C/O GLOBAL BLOOD THERAPEUTICS, INC.  
   181 OYSTER POINT BOULEVARD  
   SOUTH SAN FRANCISCO CA 94080

2. Issuer Name and Ticker or Trading Symbol
   **Global Blood Therapeutics, Inc. [GBT]**

3. Date of Earliest Transaction (Month/Day/Year)
   08/05/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)
   08/05/2020

5. Relationship of Reporting Person(s) to Issuer
   Director 10% Owner  
   Officer (give title below)  
   Chief Human Resources Officer

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person

---

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

<table>
<thead>
<tr>
<th>Title of Security (Instr. 3)</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Deemed Executed Date, if any (Month/Day/Year)</th>
<th>Transaction Code (Instr. 4)</th>
<th>Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>Ownership Code (Instr. 3 and 4)</th>
<th>Price (In $)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>08/05/2020</td>
<td></td>
<td>$ (1)</td>
<td>1,504 D $69.3185</td>
<td>950</td>
<td>0</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/07/2020</td>
<td></td>
<td>$ (1)</td>
<td>950 D $70.1008</td>
<td>0</td>
<td>0</td>
<td>D</td>
</tr>
</tbody>
</table>

---

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**

<table>
<thead>
<tr>
<th>Title of Derivative Security (Instr. 3)</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Deemed Executed Date, if any (Month/Day/Year)</th>
<th>Transaction Code (Instr. 4)</th>
<th>Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>Date Exercisable</th>
<th>Expiration Date</th>
<th>Title of Derivative Security (Instr. 5)</th>
<th>Price of Derivative Security (Instr. 6)</th>
<th>Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>Ownership Form: Direct (D) or Indirect (I) (Instr. 7)</th>
<th>Nature of Indirect Beneficial Ownership (Instr. 8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>----------------------------------------</td>
<td>-----------------------------------------------------</td>
<td>-----------------------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>------------------</td>
<td>----------------</td>
<td>----------------------------------------</td>
<td>-------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
</tbody>
</table>

---

**Explanation of Responses:**

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2020.
2. Represents the weighted average sale price of the shares sold ranging from $68.855 to $69.75 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. Represents the weighted average sale price of the shares sold ranging from $69.98 to $70.30 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

**Remarks:**

/a/Tricia Suvari, as Attorney-in-Fact  
08/07/2020

Signature of Reporting Person  
Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.